KR20240152302A - 옥사졸리디논 리포좀 조성물 - Google Patents

옥사졸리디논 리포좀 조성물 Download PDF

Info

Publication number
KR20240152302A
KR20240152302A KR1020247024600A KR20247024600A KR20240152302A KR 20240152302 A KR20240152302 A KR 20240152302A KR 1020247024600 A KR1020247024600 A KR 1020247024600A KR 20247024600 A KR20247024600 A KR 20247024600A KR 20240152302 A KR20240152302 A KR 20240152302A
Authority
KR
South Korea
Prior art keywords
akg
liposome
composition
concentration
liposome composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024600A
Other languages
English (en)
Korean (ko)
Inventor
드미트리 비. 키르포틴
알렉산더 코슈카르에브
챨스 오. 노블
다릴 씨. 드러몬드
Original Assignee
아카제라 메디신즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카제라 메디신즈, 인크. filed Critical 아카제라 메디신즈, 인크.
Publication of KR20240152302A publication Critical patent/KR20240152302A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247024600A 2021-12-22 2022-12-22 옥사졸리디논 리포좀 조성물 Pending KR20240152302A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163292899P 2021-12-22 2021-12-22
US63/292,899 2021-12-22
PCT/US2022/082290 WO2023122759A2 (en) 2021-12-22 2022-12-22 Oxazolidinone liposome compositions

Publications (1)

Publication Number Publication Date
KR20240152302A true KR20240152302A (ko) 2024-10-21

Family

ID=86903807

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024600A Pending KR20240152302A (ko) 2021-12-22 2022-12-22 옥사졸리디논 리포좀 조성물

Country Status (12)

Country Link
US (2) US20250064739A1 (enExample)
EP (1) EP4452252A4 (enExample)
JP (1) JP2025501769A (enExample)
KR (1) KR20240152302A (enExample)
CN (1) CN118900689A (enExample)
AR (1) AR128071A1 (enExample)
AU (1) AU2022420614A1 (enExample)
CA (1) CA3241952A1 (enExample)
IL (1) IL313709A (enExample)
MX (1) MX2024007588A (enExample)
WO (1) WO2023122759A2 (enExample)
ZA (1) ZA202404799B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102859152B1 (ko) * 2024-10-24 2025-09-12 주식회사 한국리포좀 합성 지질 리포좀 기반의 일본 뇌염 바이러스 백신 및 그의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
EP1656370B1 (en) * 2003-06-03 2012-08-15 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
CA3183397A1 (en) * 2020-06-18 2021-12-23 Daryl C. Drummond Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102859152B1 (ko) * 2024-10-24 2025-09-12 주식회사 한국리포좀 합성 지질 리포좀 기반의 일본 뇌염 바이러스 백신 및 그의 제조방법

Also Published As

Publication number Publication date
ZA202404799B (en) 2025-12-17
EP4452252A2 (en) 2024-10-30
CA3241952A1 (en) 2023-06-29
MX2024007588A (es) 2024-07-09
US20260083674A1 (en) 2026-03-26
EP4452252A4 (en) 2025-12-03
AU2022420614A1 (en) 2024-06-27
AR128071A1 (es) 2024-03-20
IL313709A (en) 2024-08-01
US20250064739A1 (en) 2025-02-27
JP2025501769A (ja) 2025-01-23
WO2023122759A3 (en) 2023-08-31
CN118900689A (zh) 2024-11-05
WO2023122759A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
KR102894590B1 (ko) 옥사졸리디논 화합물, 옥사졸리디논 화합물을 포함하는 리포좀 조성물 및 이의 사용 방법
AU763989B2 (en) Quinolone containing liposomes and their use as antibacterial agents
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
US20260083674A1 (en) Oxazolidinone liposome compositions
WO2018144845A1 (en) Metalloporphyrin microparticles for treatment of anemia and tropical diseases
CN115968290B (zh) 噁唑烷酮类化合物、包含噁唑烷酮类化合物的脂质体组合物、及其使用方法
HK40119430A (zh) 恶唑烷酮脂质体组合物
OA21533A (en) Oxazolidinone compounds, Liposome compositions comprising Oxazolidinone compounds and methods of use thereof.
EA048474B1 (ru) Соединения оксазолидинона, липосомальные композиции, содержащие соединения оксазолидинона, и способы их применения
HK40093312A (zh) 恶唑烷酮类化合物、包含恶唑烷酮类化合物的脂质体组合物、及其使用方法
WO2025186836A1 (en) High dosage strength of amphotericin b liposome
HK1035331B (en) Liposome composition and method for administering a quinolone

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000